Public Assessment Report

Total Page:16

File Type:pdf, Size:1020Kb

Public Assessment Report PUBLIC ASSESSMENT REPORT Decentralised Procedure Fraxiparine 0.3 2,850 I.U. anti-Xa/ 0.3 ml; Fraxiparine 0.4 3,800 I.U. anti-Xa/ 0.4 ml; Fraxiparine 0.6 5,700 I.U. anti-Xa/ 0.6 ml; Fraxiparine 0.8 7,600 I.U. anti-Xa/ 0.8 ml Procedure Number: DE/H/4762/002-005/DC Fraxodi 19000 UL / ml; 0.6 ml Fraxodi 19000 UL / ml; 0.8 ml Fraxodi 19000 UL / ml; 1.0 ml Procedure Number: DE/H/4763/001-003/DC Fraxiparine Multi 9,500 anti-Xa IU/ 1.0 ml Fraxiparine Multi 9,500 anti-Xa IU/ 1.0 ml Procedure Number: DE/H/4770/001-002/DC Active Substance: Nadroparin-Calcium Dosage Form: Solution for injection Marketing Authorisation Holder in the RMS, Germany: Aspen Pharma Trading Limited Publication: 19.11.2018 TABLE OF CONTENTS I. RECOMMENDATION ................................................................................................................ 4 II. EXECUTIVE SUMMARY ....................................................................................................... 4 II.1 Problem statement ..................................................................................................................... 4 II.2 About the product ..................................................................................................................... 4 II.3 General comments on the submitted dossier .......................................................................... 4 II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. 5 III. SCIENTIFIC OVERVIEW AND DISCUSSION ................................................................... 5 III.1 Quality aspects ........................................................................................................................... 5 III.2 Non-clinical aspects ................................................................................................................... 9 III.3 Clinical aspects .......................................................................................................................... 9 IV. BENEFIT RISK ASSESSMENT ........................................................................................... 12 DE/H/4762/002-005/DC ; Fraxiparine DE/H/4763/001-003/DC ; Fraxodi DE/H/4770/001-002/DC ; Fraxiparine Multi Public Assessment Report Page 2/12 ADMINISTRATIVE INFORMATION Fraxiparine 0.3 2,850 I.U. anti-Xa/ 0.3 ml; 0.4 3,800 I.U. Proposed name of the medicinal anti-Xa/ 0.4 ml; 0.6 5,700 I.U. anti-Xa/ 0.6 ml; 0.8 7,600 product(s) in the RMS I.U. anti-Xa/ 0.8 ml; DE/H/4762/002-005/DC Fraxodi 19,000 I.U. / ml; DE/H/4763/01-03/DC Fraxiparine Multi 9,500 anti-Xa I.U./ 1.0 ml DE/H/4770/01-02/DC Name of the drug substance (INN Nadroparin-Calcium name): Pharmaco-therapeutic group B01AD06 (ATC Code): Pharmaceutical form(s) and Solution for injection strength(s): Reference Number(s) for the DE/H/4762/02-05/DC Decentralised Procedure DE/H/4763/01-03/DC DE/H/4770/01-02/DC Reference Member State: DE Member States concerned: IE Legal basis of application: Generic Art 10.1 and 10.2 Dir 2001/83/EC Marketing Authorisation Holder Aspen Pharma Trading Limited (name and address) 3016 Lake Drive, Citywest Business Campus DUBLIN 24 Ireland Names and addresses of all Aspen Notre Dame de Bondeville manufacturer(s) responsible for 1, rue de l’Abbaye batch release in the EEA 76960 Notre Dame de Bondeville France DE/H/4762/002-005/DC ; Fraxiparine DE/H/4763/001-003/DC ; Fraxodi DE/H/4770/001-002/DC ; Fraxiparine Multi Public Assessment Report Page 3/12 I. RECOMMENDATION Based on the review of the data and the Applicant’s response to the questions raised by RMS and CMSs on quality, safety and efficacy, the RMS considers that the application for Fraxiparine (9,500 I.U. anti-Xa / 1.0 ml solution, pre-filled syringe) in the prophylaxis and/or treatment of deep venous thrombosis, is approved. II. EXECUTIVE SUMMARY II.1 Problem statement For generic application this section is not applicable. II.2 About the product The Originator product Fraxiparine ® was first authorised in Germany in 1997 and is indicated as follows:- - Perioperative thrombosis prophylaxis: o Peri- and postoperative primary prophylaxis of deep vein thrombosis in patients with low, moderate or high thromboembolic risk. o Peri- and postoperative primary prophylaxis of deep vein thrombosis in patients undergoing larger orthopedic surgeries (e.g. elective hip surgeries) - Treatment of deep vein thrombosis. - Thrombosis prophylaxis and anticoagulation with extracorporeal circulation during hemodialysis and hemofiltration. Fraxiparine has a pharmacotherapeutic group: antithrombotic ATC code: B01 AB06 The active substance of Fraxiparine is Nadroparin Calcium. Nadroparin calcium is a low molecular weight heparin (LMWH). This LMWH is prepared by depolymerisation of unfractionated porcine heparin sodium (UFH) by means of nitrous acid, followed by extraction/purification, then conversion to the calcium salt. Nadroparin calcium consists of fragments of the glycosaminoglycan, heparin, in which the relative molecular mass of the major species is between 4000 and 5000 Da. The degree of sulphation is approximately 2 per disaccharide unit. Most of the constituents have a 2-O-sulpho-δ-L- idopyranosuronic acid structure at the non-reducing end, and a 6-O-sulpho-2,5-anhydro-D-mannitol structure at the reducing end of the chains. II.3 General comments on the submitted dossier The application concerns a Marketing Authorisation Application under the Decentralised Procedure in accordance with Article 10(1) of Directive 2001/83/EC (abridged, “generic” application) with Fraxiparine ® as the reference medicinal product (RMP). The applicant, Aspen, is also the current MAH for Fraxiparine 0.3 2,850 I.U. anti-Xa/ 0.3 ml, Fraxiparine 0.4 3,800 I.U. anti-Xa/ 0.4 ml, Fraxiparine 0.6 5,700 I.U. anti-Xa/ 0.6 ml and Fraxiparine 0.8 7,600 I.U. anti-Xa/ 0.8 ml. The use of the “generic” Article 10(1) basis rather than biosimilar10(4) for the current application was chosen by the Applicant on the basis that Fraxiparine (i.e. Fraxiparine 0.3 2,850 I.U. anti-Xa/ 0.3 ml, Fraxiparine 0.4 3,800 I.U. anti-Xa/ 0.4 ml, Fraxiparine 0.6 5,700 I.U. anti-Xa/ 0.6 ml and Fraxiparine 0.8 7,600 I.U. anti-Xa/ 0.8 ml) is identical to Fraxiparine ® in all but invented name and packaging. An application according to Article 10(1) (abridged, “generic” application) is based on the information provided by the Applicant, i.e. the identical qualitative and quantitative composition in drug substance and excipients and the same pharmaceutical forms and strengths between the two products and that for DE/H/4762/002-005/DC ; Fraxiparine DE/H/4763/001-003/DC ; Fraxodi DE/H/4770/001-002/DC ; Fraxiparine Multi Public Assessment Report Page 4/12 both, there would be no change in the manufacturing process, manufacturer or manufacturing site that could lead to differences regarding safety or efficacy compared to Fraxiparine ®. The MAH needs to ensure that the new product is kept updated to reflect any changes to the reference medicinal product, including changes concerning quality of the medicinal product, throughout the life cycle of the two products. This application contains no new clinical or preclinical data, other than supporting literature where necessary. II.4 General comments on compliance with GMP, GLP, GCP and agreed ethical principles. All relevant sites have valid manufacturing authorizations or valid GMP certificates as appropriate. Hence, no GMP inspections are deemed necessary at this stage within the scope of this MAA evaluation procedure. GLP, GCP and agreed ethical principles: N/A as no clinical studies are submitted. III. SCIENTIFIC OVERVIEW AND DISCUSSION III.1 Quality aspects Drug substance Nadroparin calcium is the calcium salt of a low molecular-mass heparin prepared by nitrous acid fragmentation of heparin obtained from porcine intestinal mucosa. Nadroparin calcium is manufactured and released by Aspen Notre Dame de Bondeville, 1, rue de l’Abbaye, 76960 Notre Dame de Bondeville, France. Manufacturing Process and Process Controls In the manufacturing process description for nadroparin calcium a reference is now included that refers to the heparin sodium manufacturing process starting from pooled porcine mucosa. This is in accordance with the classification of pooled porcine intestinal mucosa as starting material for heparin and heparin derivatives (EMA/CHMPBWP/429241/2013). The conversion of heparin sodium to nadroparin calcium is performed by controlled depolymerisation of porcine heparin sodium by means of nitrous acid. The solution is then purified and converted to the calcium salt. The product is filtered, precipitated and washed with ethanol, and finally dried. The depolymerisation process is guided by pH, sodium nitrite concentration, temperature and time. Critical parameter and tests have been defined and included in the application. The depolymerisation product is purified at various operations to comply with predefined quality attributes, in particular presence of reducing groups and molecular weight distribution. Reprocessing is restricted to performed in exceptional circumstances, e.g. in case of technical failure. This is considered appropriate. The batch size of a nadroparin calcium batch derived from heparin sodium is approximately 80kg. Control of Materials Materials used in the manufacturing process are either controlled by compendial standards, standards adapted to a compendial monograph or by in-house specifications. For sodium heparin from the intended suppliers respective CoAs have been provided. Furthermore,
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Enoxaparin Sodium Solution for Injection, Manufacturer's Standard
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrLOVENOX® Enoxaparin sodium solution for injection 30 mg in 0.3 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 40 mg in 0.4 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 60 mg in 0.6 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 80 mg in 0.8 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 100 mg in 1 mL solution (100 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 300 mg in 3 mL solution (100 mg/mL), multidose vials for subcutaneous or intravenous injection PrLOVENOX® HP Enoxaparin sodium (High Potency) solution for injection 120 mg in 0.8 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection 150 mg in 1 mL solution (150 mg/mL), pre-filled syringes for subcutaneous or intravenous injection Manufacturer’s standard Anticoagulant/Antithrombotic Agent ATC Code: B01AB05 Product Monograph – LOVENOX (enoxaparin) Page 1 of 113 sanofi-aventis Canada Inc. Date of Initial Approval: 2905 Place Louis-R.-Renaud February 9, 1993 Laval, Quebec H7V 0A3 Date of Revision September 7, 2021 Submission Control Number: 252514 s-a version 15.0 dated September 7, 2021 Product Monograph – LOVENOX (enoxaparin) Page 2 of 113 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. TABLE OF CONTENTS ..............................................................................................................
    [Show full text]
  • Low Molecular Weight Heparins and Heparinoids
    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
    [Show full text]
  • Rtpa) for the Treatment of Hepatic Veno-Occlusive Disease (VOD
    Bone Marrow Transplantation, (1999) 23, 803–807 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) S Kulkarni1, M Rodriguez2, A Lafuente2, P Mateos2, J Mehta1, S Singhal1, R Saso3, D Tait4, JG Treleaven3 and RL Powles1 Departments of 1Medical Oncology, 3Haematology and 4Radiotherapy, Royal Marsden NHS Trust, Sutton, Surrey, UK; and 2Haematology Department, Hospital La Paz, Madrid, Spain Summary: clinical syndrome characterized by hyperbilirubinemia, hepatomegaly and fluid retention,2,3 and results from dam- Seventeen patients who developed hepatic veno-occlus- age to structures in zone 3 of the liver acinus.4 In patients ive disease (VOD) following hematopoietic stem cell who have undergone hematopoietic stem cell transplan- transplantation were treated with recombinant tissue tation, chemoradiotherapy-induced endothelial cell damage plasminogen activator (rtPA) with or without heparin. is likely to be responsible for the pathogenesis of vessel rtPA was started a median of 13 days post transplant obstruction.5 (range 4–35). All patients received rtPA at a dose of 10 Treatment of established VOD has primarily been sup- mg/day as a starting dose, and 12 patients also received portive and any specific measures have resulted in little heparin (1500 U bolus; then 100 U/kg/day as a continu- impact on outcome. Based on the available evidence for ous i.v. infusion). The median number of days of rtPA involvement of hemostatic mechanisms and cytokines in therapy was 2.5 (1–12). The median total serum biliru- the pathogenesis of VOD,6–8 anti-thrombotic and anti-cyto- bin level was 116 mmol/l (range 63–194) at the begin- kine agents have been assessed for their role in treatment.
    [Show full text]
  • For the Use Only of Registered Medical Practitioner Or a Hospital Or a Laboratory
    For the use only of Registered Medical Practitioner or a Hospital or a Laboratory FRAXIPARINE® Nadroparin Calcium Injection QUALITATIVE AND QUANTITATIVE COMPOSITION FRAXIPARINE® [Nadroparin calcium solution for injection (9,500 IU AXa /ml)] Pre-filled syringes: - Each pre-filled (0.2 ml) syringe contains: Nadroparin Calcium BP 1,900 IU AXa. - Each pre-filled (0.3 ml) syringe contains: Nadroparin Calcium BP 2,850 IU AXa. - Each pre-filled (0.4 ml) syringe contains: Nadroparin Calcium BP 3,800 IU AXa. Graduated pre-filled syringes: - Each pre-filled (0.6 ml) syringe contains: Nadroparin Calcium BP to 5,700 IU AXa. - Each pre-filled (0.8 ml) syringe contains: Nadroparin Calcium BP to 7,600 IU AXa. - Each pre-filled (1 ml) syringe contains: Nadroparin Calcium BP to 9,500 IU AXa. PHARMACEUTICAL FORM Solution for injection. CLINICAL PARTICULARS Therapeutic Indications The prophylaxis of thromboembolic disorders, such as: - those associated with general or orthopedic surgery - those in high risk medical patients (respiratory failure and/or respiratory infection and/or cardiac failure), hospitalised in intensive care unit. The treatment of thromboembolic disorders. The prevention of clotting during haemodialysis. The treatment of unstable angina and non-Q wave myocardial infarction. Posology and Method of Administration Particular attention should be paid to the specific dosing instructions for each proprietary Low Molecular Weight Heparin, as different units of measurement (units or mg) are used to 1 express doses. Nadroparin should therefore not be used interchangeably with other low molecular weight heparins during ongoing treatment. In addition, care should be taken to use the correct formulation of nadroparin, either single or double strength, as this will affect the dosing regimen.
    [Show full text]
  • Perioperative Management of Patients Treated with Antithrombotics in Oral Surgery
    SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 SOCIÉTÉ FRANÇAISE DE CHIRURGIE ORALE [FRENCH SOCIETY OF ORAL SURGERY] IN COLLABORATION WITH THE SOCIÉTÉ FRANÇAISE DE CARDIOLOGIE [FRENCH SOCIETY OF CARDIOLOGY] AND THE PERIOPERATIVE HEMOSTASIS INTEREST GROUP Space Perioperative management of patients treated with antithrombotics in oral surgery. RATIONALE July 2015 P a g e 1 | 107 SFCO/Perioperative management of patients treated with antithrombotic agents in oral surgery/Rationale/July 2015 Abbreviations ACS Acute coronary syndrome(s) ADP Adenosine diphosphate Afib Atrial Fibrillation AHT Arterial hypertension Anaes Agence nationale d’accréditation et d’évaluation en santé [National Agency for Accreditation and Health Care Evaluation] APA Antiplatelet agent(s) aPTT Activated partial thromboplastin time ASA Aspirin BDMP Blood derived medicinal products BMI Body mass index BT Bleeding Time cAMP Cyclic adenosine monophosphate COX-1 Cyclooxygenase 1 CVA Cerebral vascular accident DIC Disseminated intravascular coagulation DOA Direct oral anticoagulant(s) DVT Deep vein thrombosis GEHT Study Group on Hemostasis and Thrombosis (groupe d’étude sur l’hémostase et la thrombose) GIHP Hemostasis and Thrombosis Interest Group (groupe d’intérêt sur l’hémostase et la thrombose) HAS Haute autorité de santé [French Authority for Health] HIT Heparin-induced thrombocytopenia IANB Inferior alveolar nerve block INR International normalized ratio IV Intravenous LMWH Low-molecular-weight heparin(s)
    [Show full text]
  • Transition of Anticoagulants 2019
    Transition of Anticoagulants 2019 Van Hellerslia, PharmD, BCPS, CACP, Brand Generic Clinical Assistant Professor of Pharmacy Practice, Angiomax bivalirudin Temple University School of Pharmacy, Philadelphia, PA Arixtra fondaparinux Bevyxxa betrixaban Pallav Mehta, MD, Assistant Professor of Medicine, Coumadin warfarin Division of Hematology/Oncology, Eliquis apixaban MD Anderson Cancer Center at Cooper, Camden, NJ Fragmin dalteparin Lovenox enoxaparin Reviewer: Kelly Rudd, PharmD, BCPS, CACP, Pradaxa dabigatran Clinical Specialist, Anticoagulation, Bassett Medical Center, Savaysa edoxaban Cooperstown, NY Xarelto rivaroxaban From To Action Apixaban Argatroban/ Wait 12 hours after last dose of apixaban to initiate parenteral anticoagulant. In cases of Bivalirudin/ high bleeding risk, consider omitting initial bolus when transitioning to heparin infusion. Enoxaparin/ Dalteparin/ Fondaparinux/ Heparin Apixaban Warfarin When going from apixaban to warfarin, consider the use of parenteral anticoagulation as a bridge (eg, start heparin infusion or therapeutic enoxaparin AND warfarin 12 hours after last dose of apixaban and discontinue parenteral anticoagulant when INR is therapeutic). Apixaban affects INR so that initial INR measurements during the transition may not be useful for determining the appropriate dose of warfarin. Apixaban Betrixaban, Wait 12 hours from last dose of apixaban to initiate betrixaban, dabigatran, edoxaban, or Dabigatran, rivaroxaban. Edoxaban, or Rivaroxaban Argatroban Apixaban, Start apixaban, betrixaban, dabigatran,
    [Show full text]
  • The Treatment and Prevention Ofacute Ischemic Stroke
    EDITORIAL Alvaro Nagib Atallah* The treatment and prevention of acute ischemic stroke rotecting the brain from the consequences .of alternated with placebo (lower dose) and placebo injections vascular obstruction is obviously very important. every 12 hours, for 10 days. The evaluation at 6 months PHowever, how to manage this is a very complex showed that the treated group had a lower incidence rate task. Three recent studies have provided evidence that of poor outcomes, death or dependency in daily activities, I 3 should not be ignored or misinterpreted by physicians. - 45 vs. 65%. In other words, it was necessary to treat 5 The National Institute of Neurological Disorders and patients to benefit one. Evaluations at 10 days did not show Stroke rt-PA Stroke Study Groupl shows the results of a differences in death rates or haemorrhage transformation randomized, collaborative placebo-controlled trial. Six of the cerebral infarction. hundred and twenty-four patients were studied. The The Multicentre Acute Stroke Trial-Italy (MAST-I) treatment was started before 90' of the start of the stroke Group compared the effectiveness of streptokinase, aspirin or before 180'. Patients received recombinant rt-PA and a combination of both for the treatment of ischemic (alteplase) 0.9 mg/kg or placebo. A careful neurological stroke. Six hundred and twenty-two patients were evaluation was done at 24 hours and 3 months after the randomized to receive I hour infusions of 1.5 mD of stroke. streptokinase alone, the same dose of streptokinase plus There were no significant differences between the 300 mg of buffered aspirin, or 300 mg of aspirin alone for groups at 24 hours after the stroke.
    [Show full text]
  • (Dipotassium Salt) and Heparin on the Estimation of Packed Cell Volume
    J Clin Pathol: first published as 10.1136/jcp.19.2.196 on 1 March 1966. Downloaded from J. clin. Path. (1966), 19, 196 Effect of ethylene-diamine-tetra-acetic acid (dipotassium salt) and heparin on the estimation of packed cell volume C. A. PENNOCK AND K. W. JONES From the Department of Haematology, Gibson Laboratories, Radcliffe Infirmary, Oxford SYNOPSIS The effect of varying concentrations of ethylene-diamine-tetra-acetic acid (E.D.T.A.) (dipotassium salt) and heparin on the estimation of packed cell volume has been studied using a microhaematocrit method. Varying concentrations of E.D.T.A. can produce serious errors in estimation of packed cell volume (P.C.V.) and reliable results are only obtained within the range of 1 to 2 mg./ml. Heparin is a more suitable anticoagulant for this investigation as varying the con- centration has little effect. Storage with either anticoagulant at suitable concentrations for 24 hours at room temperature has little influence on the results. The estimation ofthe packed cell volume (P.C.V.) is bottles are often returned to this laboratory contain- regarded as a reliable investigation in the diagnosis ing less than the recommended amount of blood.copyright. of anaemia, and errors in the estimation of mean Ethylene-diamine-tetra-acetic acid is known to corpuscular haemoglobin concentration (M.C.H.C.) cause distortion and shrinkage of red cells and are thought to be due more often to errors in the to affect the estimation of P.C.V. by conventional estimation of haemoglobin than of the P.C.V.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Anticoagulant-Related Subdural Hematoma in Patients with Mechanical Heart Valves
    Neurology Asia 2005; 10 : 13 – 19 ORIGINAL ARTICLES Anticoagulant-related subdural hematoma in patients with mechanical heart valves GVS Chowdary MD DM, T Jaishree Naryanan MD PhD, *P Syed Ameer Basha MBBS MCh, *TVRK Murthy MBBS MCh, JMK Murthy MD DM Department of Neurology and *Neurosurgery, The Institute of Neurological Sciences, CARE Hospital, Nampally, Hyderabad, India Abstract Introduction: There is uncertainty on the timing of surgery in patients with anticoagulant-related subdural hematoma (SDH) and also on the timing of reintroduction of anticoagulants. Methods: We retrospectively analyzed records of 7 patients with mechanical heart valves and anticoagulant-related SDH. Results: Of the 7 patients, 6 (83%) survived to discharge with good functional outcome, modified Rankin Scale 0-1. Reversal of anticoagulation (INR < 1.4) could be achieved in 5 patients. Three patients with minimal deficit and no CT evidence of midline shifts were managed non-surgically. Three patients had surgical evacuation, 2 with acute SDH and midline shift and one patient with bilateral subacute SDH and no midline shift. The mean duration of anticoagulation withholding was 20.3 days (range 8-28). None had thrombolic events while off anticoagulation. Five patients were restarted on acenocumarol/warfarin when follow-up cranial CT showed decrease or resolution of SDH. High risk for thromboembolism was the indication for early anticoagulation in the patient with mitral position of the prosthesis and atrial fibrillation. One of the patient with subacute SDH who had post surgical residual SDH and echocardiographic evidence of valve dysfunction was initially started on unfractionated heparin followed by nadroparin calcium and subsequently on acenocumarol.
    [Show full text]
  • Antithrombotic Therapy During Pregnancy
    ARC Journal of Pharmaceutical Sciences (AJPS) Volume 1, Issue 2, July – September 2015, PP 16-20 www.arcjournals.org Antithrombotic Therapy During Pregnancy Sihana Ahmeti Lika1*, Bujar H. Durmishi2, Agim Shabani2, Merita Dauti1, Ledjan Malaj3 1 Faculty of Medical Sciences, Department of Pharmacy, State University of Tetova, Ilindeni Str. n.n., 1200 Tetova, R. of Macedonia [email protected] 2 Faculty of Mathematical - Natural Sciencese, Department of Chemistry, State University of Tetova, Ilindeni Str. n.n., 1200 Tetova, R. of Macedonia 3 Faculty of Pharmacy, Medical University of Tirana, of Albania Abstract: Antithrombotic therapy is the main therapy for acute deep vein thrombosis. The objectives of anticoagulant therapy in the initial treatment are to prevent thrombus extension and early and late recurrences of deep vein thrombosis and pulmonary embolism. The main objective of our study is to analyze the usage of low molecular weight heparins in women, during the period of pregnancy. Our study, represents a retrospective study, which was undertaken during 01 July – 31 December 2013, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetova. Among of 817 pregnant women, 277 of them received anticoagulant therapy, respectively Low Molecular Weight Heparins. 119 of them were patients with risky pregnancy and 68 were with the diagnosis Hypercoagulable State. Keywords: Antithrombotics, Deep Vein Thrombosis, Pregnancy, Low Molecular Weight Heparins. Abrevations LMWH Low molecular weight heparins VT venous thromboembolism 1. INTRODUCTION There are two main adverse expriences that are associated with thrombophilia and pregnancy. These are VT and pregnancy complications associated with placental infarction, including miscarriage, intrauterine growth restriction, preeclampsia, abruption, and intrauterine death [1].
    [Show full text]